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http://dx.doi.org/10.1016/j.jacl.2014.10BACKGROUND: Restricted intakes of saturated and trans-fatty acids is emphasized in heart-healthy
diets, and replacement with poly- and monounsaturated fatty acids is encouraged.
OBJECTIVE: To compare the effects of polyunsaturated fatty acid–rich corn oil (CO) and monoun-
saturated fatty acid–rich extra-virgin olive oil (EVOO) on plasma lipids in men and women (N 5 54)
with fasting low-density lipoprotein cholesterol (LDL-C) $130 mg/dL and ,200 mg/dL and triglyc-
erides (TG) #350 mg/dL.
METHODS: In a double-blind, randomized, crossover design (21-day treatments, 21-day washout
between), 4 tablespoons/day CO or EVOO were provided in 3 servings study product/day (muffin,
roll, yogurt) as part of a weight-maintenance diet (w35% fat, ,10% saturated fat, ,300 mg choles-
terol). Subjects ate breakfast at the clinic every weekday throughout the study. Lunches, dinners, and
snacks (and breakfasts on weekends) were provided for consumption away from the clinic.
RESULTS: Baseline mean (standard error) lipids in mg/dL were: LDL-C 153.3 (3.5), total choles-
terol (total-C) 225.7 (3.9), non–high-density lipoprotein (non–HDL)-C 178.3 (3.7), HDL-C 47.4 (1.7),
total-C/HDL-C 5.0 (0.2), and TG 124.8 (7.2). CO resulted in significantly larger least-squares mean %
changes (all P , .001 vs EVOO) from baseline in LDL-C 210.9 vs 23.5, total-C 28.2 vs 21.8, non–
HDL-C 29.3 vs 21.6, and total-C/HDL-C 24.4 vs 0.5. TG rose a smaller amount with CO, 3.5 vs
13.0% with EVOO (P 5 .007). HDL-C responses were not significantly different between conditions
(23.4 vs 21.7%).
CONCLUSION: Consumption of CO in a weight-maintenance, low saturated fat and cholesterol diet
resulted in more favorable changes in LDL-C and other atherogenic lipids vs EVOO.
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50 Journal of Clinical Lipidology, Vol 9, No 1, February 2015Introduction TreatmentsCorn oil (CO) contains the highest naturally occurring
phytosterol levels of the refined vegetable oils (0.97 g/100 g
oil per the US Department of Agriculture National Nutrient
Database for Standard Reference), and is rich in poly-
unsaturated fatty acids (PUFA).1,2 Restriction of intakes of
saturated fatty acids (SFA) and trans-fatty acids is empha-
sized in cholesterol-lowering, heart-healthy diets, whereas
consumption of unsaturated fatty acids is emphasized.3–5
PUFA, in place of SFA or carbohydrates, has been
shown to lower the plasma low-density lipoprotein choles-
terol (LDL-C) concentration and to be associated with
reduced risk for coronary heart disease (CHD) in prospec-
tive cohort studies.6–8 The Mediterranean dietary pattern,
high in monounsaturated fatty acids (MUFA)-rich olive
oil, has also been associated with reduced CHD risk in
epidemiological and clinical studies,9–11 and, when
substituted for SFA or carbohydrates, MUFA significantly
reduces LDL-C without lowering high-density lipoprotein
(HDL)-C.7,12,13 The degree of unsaturation that is most
effective for providing beneficial lipid changes and protec-
tion from CHD is controversial.14–16
It is often underappreciated that, although food sour-
ces, including dietary oils, may be rich in 1 type of fatty
acid, they are not 100% SFA, MUFA, or PUFA. Thus, it is
important to consider the effects of specific food choices,
particularly with regard to the effects of substitution of
1 food or food component for another. The present,
single-center, randomized, controlled, double-blind, 2-
period, crossover feeding trial compared the effects on
lipoprotein lipids of 2 mostly unsaturated dietary oils, CO
and extra-virgin olive oil (EVOO), incorporated into a
weight-maintenance diet containing w35% of kcal
from fat, ,10% SFA, and ,300 mg/d cholesterol in
men and women with hypercholesterolemia at a single
clinical research center (Biofortis Clinical Research,
Addison, IL).Methods
Study design
This study was conducted according to Good Clinical
Practice Guidelines, the Declaration of Helsinki (2000),
and the United States 21 Code of Federal Regulations
(ClinicalTrials.gov identifier: NCT01925716). The study
protocol and informed consent documents were approved
by an institutional review board (Quorum Review
IRB, Seattle, WA). A signed informed consent form
and authorization for disclosure of protected health in-
formation were obtained from all subjects before
protocol-specific procedures were carried out. Staff and
subjects remained blinded to treatment throughout the
trial.The study included 2 21-day treatment periods and a 21-
day washout between treatments. During the treatment
periods, 4 tablespoons per day (w54 g) of CO (528 mg
phytosterols, 29.7 g PUFA) or EVOO (120 mg phytosterols,
5.6 g PUFA) were provided in 3 servings of study products
per day (muffin, dinner roll, yogurt) as part of a weight-
maintenance diet. The fatty acid and sterol compositions of
the CO and EVOO as determined by Covance Laboratories
(Madison, WI) are shown in Tables 1 and 2, respectively,
and the nutrient compositions of the study products are pre-
sented in Table 3. Subjects reported to the clinic on
Monday through Friday during both treatment periods for
breakfast, including 1 serving of study product, between
0630 and 0930 AM. Subjects were provided lunch, dinner,
and a snack, including 2 additional servings of study prod-
uct, 1 of which was consumed with lunch and 1 with din-
ner, for consumption away from the clinic. Meals for
Saturday and Sunday were dispensed on Fridays for con-
sumption outside the clinic.
Meal plans were determined for the subjects based on
energy needs using the Mifflin-St Jeor equation17 to esti-
mate resting energy expenditure, and summed with the
average estimated energy expended in physical activity as
assessed by the Stanford 7-day activity questionnaire.18 A
range of menu plans in 200-kcal increments from 1800 to
3600 kcal/d was created. The diets were designed to pro-
vide w35% energy/d from fat (,10% SFA and ,300 mg
cholesterol),w15% energy/d from protein, andw50% en-
ergy/d from carbohydrate (with total daily fiber intakew15
to 20 g/d). All foods in the rotating menus were identical in
the 2 treatment conditions with the exception of the oils
used to prepare the study foods (dinner roll, muffin, and
yogurt). The average daily energy and nutrient intakes for
the rotating menus were analyzed using Food Processor
SQL Nutrition Analysis and Fitness Software (version
10.4.0, ESHA Research, Salem, OR). Subjects were also
given a list of non-caloric beverages for ad libitum con-
sumption. They were instructed to consume all of the study
foods in their entirety and to avoid consuming any addi-
tional food or nonspecified drink items. In the event that
a subject consumed a nonstudy food or caloric beverage,
he or she was instructed to record the intake of the food/
beverage item in a provided notebook and return to the
clinic the uneaten portion of the nonstudy food or the label
of the nonstudy item.
Compliance with the dietary instructions was evaluated
by the study staff according to the returned food items from
the lunch and dinner meals and snack; study product
compliance was recorded as the percentage of scheduled
intakes of study products consumed. Body weight was
assessed weekly during each treatment period, and meal
plans were adjusted, as needed, to ensure each subject
maintained a stable body weight. Subjects were also
instructed to maintain their usual physical activity level
Table 2 Sterol composition of CO and EVOO*
Sterol
CO EVOO
mg per 100 g
Total sterols 989 198
Cholesterol 1.7 ,1.0
Campesterol 178 7.5
Stigmasterol 68.8 2.0
Beta-sitosterol 617 146
Brassicasterol ,1.0 ,1.0
Other sterols/stanols 125 42.7
CO, corn oil; EVOO, extra-virgin olive oil.
*Results are from analyses performed by Covance Laboratories
(Madison, WI).
Table 1 Fatty acid composition of CO and EVOO for fatty
acids present at levels .0.05 g per 100 g in either oil*
Fatty Acids, calculated as TG
CO EVOO
g per 100 g
Total fatty acids 100 99.9
SFA 13.4 17.0
MUFA 28.1 68.2
PUFA 54.0 10.2
Trans 0.33 ,0.02
16:0 Palmitic 11.5 14.4
16:1 Palmitoleic 0.10 1.48
17:0 Heptadecanoic 0.06 0.07
18:0 Stearic 1.74 2.76
9c-18:1 Oleic 28.4 66.8
Total 18:1 cis 29.0 69.6
18:2 Linoleic 55.6 10.0
Total 18:2 trans 0.24 ,0.02
18:3 Linolenic 0.95 0.69
Total 18:3 trans 0.07 ,0.02
20:0 Arachidic 0.40 0.41
20:1 Eicosenoic 0.27 0.25
22:0 Behenic 0.12 0.12
24:0 Lignoceric 0.16 0.06
CO, corn oil; EVOO, extra-virgin olive oil; MUFA, monounsaturated
fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty
acids; TG, triglycerides.
*Results are from analyses performed by Covance Laboratories
(Madison, WI).
Maki et al Corn & olive oil in hypercholesterolemia 51and other habits throughout the trial, and queries regarding
compliance with these requests were made at weekly
weigh-in visits.
Subjects
Eligible subjects were normally active men and nonpreg-
nant, nonlactating women 18 to 74 years of age, inclusive,
with body mass index $18.5 and ,35.0 kg/m2, fasting
LDL-C $130 mg/dL and ,200 mg/dL and fasting triglyc-
erides (TG) #350 mg/dL. The subjects were required to
have calculated energy needs of$1800 kcal/d.17,18 Individ-
uals who reported using, within 4 weeks before screening,
medications intended to alter the lipid profile, or weight-
loss drugs or programs, were not included, nor were those
who used any foods or dietary supplements that might alter
lipid metabolism within 2 weeks of screening. If a subject
had an active infection or used antibiotics within 5 days
of screening or any of the scheduled lipid blood draws,
that visit was rescheduled and, where applicable, was
extended until at least 5 days after the infection resolved
or the antibiotic use had been completed.
Laboratory measurements
Laboratory measurements were conducted by EMH
Reference Laboratory (Elmhurst, IL). Serum chemistryand hematology profiles were measured at screening; fast-
ing (12 6 2 hours, water only) lipid profiles were measured
twice on separate days at baseline and the end of each 21-
day treatment period. The lipid profile, including total-C,
LDL-C, HDL-C, and TG, was analyzed according to the
Standardization Program of the Centers for Disease Control
and Prevention and the National Heart, Lung and Blood
Institute.19 LDL-C concentration in mg/dL was calculated
according to the Friedewald equation:20 LDL-C 5 total-C
– HDL-C –TG/5. Non–HDL-C was calculated as non–
HDL-C 5 total-C – HDL-C.
Statistical analysis
All statistical analyses were conducted using SAS for
Windows (version 9.1.3; Cary, NC). Efficacy analyses were
performed in the group of randomized subjects who
provided at least 1 postrandomization outcome data point
during each treatment period (ie, efficacy-evaluable popu-
lation). Safety analyses were completed for data collected
from all subjects who were randomized and consumed at
least 1 serving of study product.
An evaluable sample of 47 subjects was expected to
provide 85% power (alpha 5 0.05, 2-tailed) to detect a
difference between treatments of 4% in the change in LDL-
C (primary outcome variable) from baseline to the end of
the treatment period, assuming a 9% pooled standard
deviation. A sample of 57 subjects was randomized to
allow for attrition and noncompliance. A randomization list
for treatment sequence was generated using SAS with the
seed number recorded. The a priori estimated difference in
LDL-C response between the CO and EVOO treatments
was 5.3%, based on calculations from Yu et al21 and De-
monty et al.22 Other lipoprotein lipid and hemodynamic
variables were considered secondary outcomes.
All tests of significance, unless otherwise stated, were
performed at alpha 5 0.05, 2-sided. Baseline comparability
of treatment sequence groups for demographic, lipid, and
blood pressure variables were assessed by analysis of
variance, chi-square tests, or Fisher exact tests, as appro-
priate. The primary outcome variable was the least squares
Table 3 Nutrient composition of study products
Energy or nutrient Muffin* (99.7 g per item)‡ Dinner roll† (92.2 g per item)‡ Yogurt (21.5 g per item)
Total energy, kcal 338.7 351.7 275.6
Carbohydrate, g 39.1 39.6 16.0
Protein, g 4.3 5.9 5.0
Fat, g 18.7 19.1 21.0
SFA, g (CO/EVOO) 2.4/2.6 2.5/2.7 2.7/2.9
MUFA, g (CO/EVOO) 5.1/13.4 5.2/13.5 5.8/15.3
PUFA, g (CO/EVOO) 10.2/2.1 10.3/2.2 11.5/2.2
Fiber, g 2.0 2.0 0.0
Cholesterol, mg 0.0 0.0 0.0
CO, corn oil; EVOO, extra-virgin olive oil; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids.
*There were 2 flavors of muffins (carrot cake and pumpkin) that differed slightly in total energy, carbohydrate, protein, PUFA, and fiber contents. The
values shown represent an average of the 2 flavors for those nutrients and energy. The differences between flavors were small and unlikely to be material.
†There were 2 flavors of dinner rolls (rosemary garlic and wheat) that differed slightly in total energy, carbohydrate, protein, fat, SFA (differed in
EVOO rolls only), MUFA, PUFA, and fiber contents. The values shown represent an average of the 2 flavors for those nutrients and energy. The differences
between flavors were small and unlikely to be material.
‡Gram weights of muffin and dinner roll were before baking. Variability in moisture loss during baking resulted in slight differences in postbake
weights.
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values on days 27 and 0) to the end of each treatment
period (average of values on days 19 and 21 in each 21-day
treatment period) in LDL-C concentration, and secondary
outcome variables included LSM percent changes from
baseline in total-C, HDL-C, non–HDL-C, TG, and the
total-C/HDL-C ratio. Responses to treatment for the
primary and secondary outcome variables, resting hemo-
dynamic measurements, and body weight were assessed
with repeated measures analysis of variance or covariance
using SAS Proc Mixed, as were dietary intakes calculated
from each subject’s energy level menu. Initial repeated
measures models contained terms for treatment, sequence,
and treatment by sequence as fixed effects, with subject
modeled as a random effect, and baseline (where available)
as a covariate. Models were reduced in a stepwise manner
until only significant (P , .05) terms or treatment re-
mained. There was no evidence of clinically important het-
erogeneity in treatment response by sequence, thus the data
from the 2 sequence groups were pooled, and the efficacy
results are presented by treatment. Frequencies of adverse
events in the 2 treatment conditions were compared using
McNemar’s test.
Assumptions necessary for application of parametric
statistical procedures were investigated for each response
measurement, and no marked departures were observed, so
raw (untransformed) data were analyzed. Missing data were
not imputed; thus, only observed data were included in the
statistical models.Results
Of the 109 subjects screened, 57 met the inclusion
criteria and were randomized (Fig. 1) to treatment in the 2
sequences of CO/EVOO (n 5 29) and EVOO/CO (n 5 28).
Dates for first subject screened and final subject visit wereMarch 8, 2013, and August 1, 2013, respectively. A total of
54 subjects completed the study and were included in the
efficacy evaluable sample. One subject discontinued
because of an intolerance to eggs in the study meals,
another discontinued for financial reasons, and a third
discontinuation was at the investigator’s discretion (subject
behaved erratically toward staff and other subjects). Mean
compliance with consumption of study products during
the CO and EVOO treatments, respectively, was 96.2%
(0.5%) and 97.5% (0.2%). The main reasons for missed
consumption of study products were missed clinic appoint-
ments from a storm with flooding (1 day) and a power
outage (1 separate day), each of which caused some
subjects to miss a single day of study foods. There were
no significant differences in compliance between treatment
sequences or CO and EVOO conditions (P 5 .208). Demo-
graphic and baseline characteristics of the subjects are pre-
sented in Table 4. The mean age of the subjects was
53.8 years; a majority were female (64.8%) and of non-
Hispanic white race/ethnicity (75.9%). Average total en-
ergy and nutrient intakes according to the rotating menus
for each subject’s energy level, presented in Table 5,
confirmed that during the CO treatment period compared
with the EVOO period, subjects consumed a significantly
(P , .001 for all) larger percentage of energy from PUFA
(10.2 vs 3.3%) and less SFA (8.0 vs 8.2%) and MUFA
(9.8 vs 16.8%).
Mean fasting lipoprotein lipid levels at baseline, end of
treatment, the LSM percent changes from baseline to the end
of each treatment as well as differences between conditions
in responses are shown in Table 6. Consumption of CO prod-
ucts, compared with EVOO products, resulted in signifi-
cantly larger reductions in LDL-C (27.4%), non–HDL-C
(27.7%), and total-C (26.4%) (P , .001 for all). Further-
more, the total-C/HDL-C ratio was significantly reduced
by 4.4% with CO compared with a slight 0.5% increase
with EVOO (P , .001), and consumption of CO resulted
Figure 1 Subject disposition diagram. CO, corn oil; EVOO, extra-virgin olive oil.
Table 4 Demographic and selected baseline characteristics
of subjects*
Characteristic Value, N 5 54
n (%)
Male 19 (35.2)
Female 35 (64.8)
Race/ethnicity
Non-Hispanic White 41 (75.9)
Non-Hispanic Black/African American 8 (14.8)
Non-Hispanic Other 3 (5.6)
Hispanic/Latino 2 (3.7)
Mean (SEM)
Age, y 53.8 (1.3)
Body mass index, kg/m2 28.2 (0.5)
Fasting plasma glucose, mg/dL 96.7 (1.1)
Physical activity MET score above basal 91.1 (3.5)
MET, metabolic equivalent; SEM, standard error of the mean.
*Baseline for lipids, heart rate, blood pressure, and body weight
are shown in Tables 6 and 7, as appropriate.
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(3.5%) compared with EVOO (13.0%) (P 5 .007). HDL-C
responses were not significantly different between condi-
tions (23.4 vs 21.7% for CO vs EVOO). Figure 2 depicts
the percentage of subjects during CO or EVOO conditions
with an LDL-C reduction of at least 5%.
Results of the assessments of vital signs (systolic and
diastolic blood pressures and heart rate) and body weight at
baseline, end of treatment, the LSM changes from baseline
to the end of each treatment, and the difference in responses
are shown in Table 7. Small declines from baseline in sys-
tolic blood pressure and body weight occurred during both
treatment conditions, but there were no statistically signif-
icant differences in responses between treatments. Diastolic
blood pressure rose by a mean of 0.1 mm Hg with CO
compared with a mean decline of 1.5 mm Hg with
EVOO (P 5 .042). Mean heart rate also increased slightly
during the CO condition (1.5 beats/min) compared with a
reduction in the EVOO condition (0.6 beats/min)
(P 5 .022).
A total of nine subjects (15.8%) reported at least 1
adverse event during the CO treatment and 12 subjects
(21.4%) during the EVOO treatment (P 5 .467). Adverse
events that were experienced by .3% of subjects in a treat-
ment condition included change in bowel habits (EVOO,
n 5 2), constipation (EVOO, n 5 3), diarrhea (CO,
n 5 3; EVOO, n 5 1), flatulence (CO, n 5 2; EVOO,
n5 1), nausea (CO, n5 2; EVOO, n5 1), weight decrease
(CO, n 5 2; EVOO, n 5 1), myalgia (CO, n 5 1; EVOO,
n 5 2), rhinitis (CO, n 5 2), and upper respiratory tract
infection (EVOO, n 5 3). None of the adverse events
was classified as severe or serious. In terms of relationship
to study product, 9 events were classified as probably ordefinitely related to consumption of EVOO (change in
bowel habits [n 5 1], constipation [n 5 3], dyspepsia
[n 5 1], weight decrease [n 5 1], and weight increase
[n 5 1]) and 2 events with CO (both weight decrease).Discussion
The results of this study demonstrate that w54 g/d of
CO, when consumed as part of a weight-maintenance, low-
SFA and cholesterol diet by men and women with hyper-
cholesterolemia resulted in significantly larger reductions
Table 5 Average daily energy and nutrient intakes for
subjects (N 5 54) during the CO and EVOO treatment periods
(calculated from the menus for each subject’s energy level)*,†
Parameter
CO EVOO
Mean (SEM)
Energy (kcal/d) 2483 (63.1) 2483 (63.1)
Carbohydrate (% energy) 50.0 (0.1) 50.0 (0.1)
Protein (% energy) 16.9 (0.1) 16.9 (0.1)
Total fat (% energy) 34.0 (0.1) 34.0 (0.1)
SFA (% energy) 8.0 (0.1) 8.2 (0.1)‡
MUFA (% energy) 9.8 (0.3) 16.8 (0.4)‡
PUFA (% energy) 10.2 (0.2) 3.3 (0.1)‡
Ratio of PUFA/SFA 1.3 (0.1) 0.4 (0.0)‡
Dietary fiber (g/d) 22.7 (0.4) 22.7 (0.4)
Cholesterol (mg/d) 132.4 (4.4) 132.4 (4.4)
CO, corn oil; EVOO, extra-virgin olive oil; MUFA, monounsaturated
fatty acids; PUFA, polyunsaturated fatty acids; SEM, standard error of
the mean; SFA, saturated fatty acids.
*Food Processor SQL Nutrition Analysis and Fitness Software
(version 10.4.0, ESHA Research, Salem, OR). Calculations were based
on the menus during the final week of participation and assumed
100% compliance with study food consumption. The number of sub-
jects at each kcal level was: 1800 (n 5 5), 2000 (n 5 6), 2200
(n 5 10), 2400 (n 5 10), 2600 (n 5 11), 2800 (n 5 4), 3000
(n 5 2), 3200 (n 5 3), 3400 (n 5 2), 3600 (n 5 4).
†Values differed between treatments only for the nutrients which
differed between study products.
‡P , .001 between CO and EVOO.
Figure 2 Percentage of subjects with reductions from baseline in
low-density lipoprotein cholesterol (LDL-C) of $5% according to
corn oil (CO) or extra-virgin olive oil (EVOO) treatment.
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HDL-C ratio compared with EVOO. These results are
consistent with those from a crossover study conducted in
28 healthy young men (19 to 31 years of age) who, for 2
weeks, consumed a diet with 80 g CO/d vs a MUFA-rich
mixture of 68 g olive oil plus 12 g sunflower oil/d as the
main fat source in a normal, balanced diet. In that trial, the
PUFA-rich diet, but not the MUFA-rich diet, resulted in
significant decreases from baseline in total-C, LDL-C, and
very-low-density lipoprotein-C levels (P , .01).23 Howev-
er, another previously published comparison of CO, olive
oil, and canola oil failed to demonstrate a significantTable 6 Fasting lipoprotein lipids at baseline, EOT, LSM percent ch
responses (N 5 54)
Parameter
Baseline, mg/dL CO EOT, mg/dL EVOO EOT,
Mean (SEM)
LDL-C 153.3 (3.5) 136.1 (3.3) 147.1 (3.4
Non–HDL-C 178.3 (3.7) 161.4 (3.9) 174.7 (3.8
Total-C 225.7 (3.9) 206.8 (4.0) 221.1 (4.0
HDL-C 47.4 (1.7) 45.5 (1.5) 46.3 (1.6
TG 124.8 (7.2) 126.6 (8.7) 138.0 (9.5
Total-C/HDL-C 5.0 (0.2) 4.8 (0.2) 5.0 (0.2
CO, corn oil; Diff, difference; EOT, end of treatment; EVOO, extra-virgin o
lipoprotein cholesterol; LSM, least squares mean; non–HDL-C, non–high-densit
cholesterol; TG, triglycerides.difference in LDL-C responses between oils when
consumed as two-thirds of the total daily fat for 32 days
by 15 men and women with hypercholesterolemia and a
mean age of 61 years, as part of the National Cholesterol
Education Program Step 2 diet (,30% kcal from fat,
,7% kcal from SFA, cholesterol , 200 mg/d).24
HDL-C responses were not significantly different be-
tween CO and EVOO conditions in the present trial. Some
studies have shown that PUFA-rich, but not MUFA-rich, oils
decrease HDL-C,25 and olive oil consumption has also been
reported to maintain, or increase, levels of HDL-C when
compared with carbohydrates.13 When compared directly
with PUFA-rich oils, the effects of olive oil on HDL-C
have been inconsistent. In Lichtenstein et al’s comparison
of CO, olive oil, and canola oil, HDL-C increased signifi-
cantly from baseline with CO and canola oil consumption
(9% and 7%, respectively), whereas a rise in HDL-C of
4% with olive oil did not reach statistical significance.24 Ho-
well et al’s examination of lipid responses to CO and olive
oil alone or with supplemental phytosterols indicated no sig-
nificant difference in HDL-C between treatments.26 TG con-
centrations in the present trial increased with both the CO
and EVOO conditions, possibly as a result of increasing car-
bohydrate content as a percentage of energy consumed,
compared with the subjects’ habitual diets. However, theanges from baseline, and differences between treatments in
mg/dL CO, %D EVOO, %D % Diff.
P valueLSM (SEM)
) 210.9 (1.5) 23.5 (1.5) 27.4 ,.001
) 29.3 (1.4) 21.6 (1.4) 27.7 ,.001
) 28.2 (1.1) 21.8 (1.1) 26.4 ,.001
) 23.4 (1.2) 21.7 (1.2) 21.7 .192
) 3.5 (4.2) 13.0 (4.2) 29.5 .007
) 24.4 (1.5) 0.5 (1.5) 24.9 ,.001
live oil; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
y lipoprotein cholesterol; SEM, standard error of the mean; Total-C, total
Table 7 Vital signs and body weight at baseline, EOT, LSM changes from baseline, and differences between treatments in responses
(N 5 54)
Parameter
Baseline CO EOT EVOO EOT CO, D EVOO, D Diff.
P valueMean (SEM) LSM (SEM)
SBP, mm Hg 119.5 (1.6) 118.3 (1.6) 117.7 (1.6) 21.2 (1.0) 21.9 (1.0) 0.7 .443
DBP, mm Hg 75.3 (1.2) 75.4 (1.3) 73.8 (1.2) 0.1 (0.8) 21.5 (0.8) 1.6 .042
Heart rate, beats/min 68.7 (1.1) 70.2 (1.2) 68.1 (1.0) 1.5 (0.7) 20.6 (0.7) 2.1 .022
Body weight, kg 79.5 (1.9) 78.9 (1.9) 79.0 (1.8) 20.6 (0.2) 20.5 (0.2) 20.1 .746
CO, corn oil; DBP, diastolic blood pressure; Diff, difference; EOT, end of treatment; EVOO, extra-virgin olive oil; LSM, least squares mean; SBP, systolic
blood pressure; SEM, standard error of the mean.
Maki et al Corn & olive oil in hypercholesterolemia 55degree of TG elevation was smaller with CO compared with
EVOO. Although the subjects in this trial were generally not
hypertriglyceridemic, these results suggest a potential
benefit of CO for minimizing TG elevations.
One potential factor contributing to the lipid effects of
CO is its higher phytosterol content relative to EVOO
(528 mg vs 120 mg in the 4 tablespoons of oil administered
per day). Phytosterols have been shown to alter intestinal
cholesterol metabolism through several mechanisms,
including competition with cholesterol for incorporation
into mixed micelles; modulation of the effects of Niemann-
Pick C1–like 1 transporters and scavenger class B type 1
receptors to lower intestinal sterol uptake. Also, absorption
of sterols into enterocytes triggers upregulation of adeno-
sine triphosphate binding cassette G5 and G8 transporters,
thereby increasing the efflux of sterols into the intestinal
lumen for excretion.27–29
Ostlund and colleagues evaluated cholesterol absorption
after a single meal test with native CO and CO stripped of
phytosterols, and showed significantly greater cholesterol
absorption after consumption of the phytosterol-free CO
(P 5 .005).30 Howell et al addressed the hypothesis that
phytosterols in CO accounted for the differential action
on lipoprotein lipids compared with OO by administering
10-day diets containing CO, olive oil, and olive oil supple-
mented with phytosterols at twice the level found naturally
in CO to 16 normolipidemic men and women.26 Total-C
levels were higher after both olive oil treatments vs CO,
and nonsupplemented olive oil also resulted in significantly
greater LDL-C compared with CO. Inclusion of the phytos-
terol mixture with olive oil appeared to suppress the LDL-C
difference between olive oil and CO. These results sug-
gested that phytosterols were responsible for at least part
of the lipid effects of CO compared with olive oil.
The higher PUFA content of CO vs EVOO (29.7 g vs
5.6 g PUFA in the 4 tablespoons of oil administered per day)
would also be expected to contribute to the difference in
lipoprotein lipid responses between treatments. Because
EVOO contains a slightly higher proportion of SFA than CO,
the daily intake of SFAwas expected to be 7.2 g for CO and
9.2 g for EVOO, resulting in a 0.7% difference in energy
intake based on the average energy intake of 2483 kcal/d.
However, analysis of study menus indicated that the meandifference between treatments was 0.2% of energy, which is
likely to be attributable to rounding error and slight
differences in percentages of energy contributed by different
fatty acids across energy intake categories. Using the
equations from Yu et al,21 which predict the amount of
cholesterol lowering attributable to differences in dietary in-
takes of MUFA, PUFA, and specific SFA (12:0, 14:0, 16:0,
18:0), consumption of CO, compared with EVOO, was pre-
dicted to result in a difference in LDL-C of 22.4% at the
average energy intake of the subjects. The observed differ-
ence between CO and EVOO conditions for LDL-C was
27.4%, leaving 5.0% of the effect, which might be attribut-
able to other components of the CO and EVOO, including
the higher phytosterol content of CO.
Research regarding the effects of CO vs olive oil on
cardiovascular outcomes has been limited to date. An early
randomized, controlled trial suggested a possible adverse
effect of CO consumption on cardiovascular disease, but
several issues suggest that those results should be interpreted
with caution.31 Rose et al examined the effects on lipids and
cardiovascular events of consumption of CO or olive oil in a
restricted fat diet comparedwith a control group that received
no advice on dietary fat in 80 patients with a history of
myocardial infarction or angina. Serum cholesterol levels
declined significantly in the CO group throughout the study,
whereas cholesterol rose slightly (but not significantly) in the
control and olive oil groups.31 Among the proportion of pa-
tients still enrolled at 2 years of follow-up, fewer remained
free from major cardiac events in the olive oil (57%) and
CO groups (52%) vs the control group (75%). Many of the
patients complained of side effects (distaste, nausea, diar-
rhea) with the prescribed oil supplements. This led to sub-
stantially diminished compliance with oil consumption; by
the end of the study, the estimated amount of oil consumed
was w50 g/d compared with the 80 g/d prescribed. Also,
there was a relatively large number of dropouts for noncar-
diac reasons, which was the rationale for expressing cardio-
vascular outcomes as a proportion of only those subjects still
in the trial (approximately half of the original participants).
The Minnesota Coronary Survey was a randomized trial
that compared the effects of a 39% fat control diet (18%
SFA, 5% PUFA, 16% MUFA, 446 mg/d cholesterol) with a
38% fat treatment diet (9% SFA, 15% PUFA, 14% MUFA,
56 Journal of Clinical Lipidology, Vol 9, No 1, February 2015166 mg/d cholesterol) on serum cholesterol and incidence
of myocardial infarction, sudden death, and all-cause
mortality among 9057 patients in 6 mental hospitals and
one nursing home.32 The mean duration on each diet was
384 days, although some subjects were followed as long
as 4.5 years, and mean serum cholesterol declined an
average of 14.5% for the treatment group and was essen-
tially unchanged in the control group (decline of 0.7%).
There were no significant differences between groups in
the primary endpoints of acute and silent myocardial infarc-
tions and sudden deaths. The authors proposed that a reduc-
tion might have been detected if the treatment period had
been longer, and/or if the population was limited to persons
in the age range most likely to benefit (35 to 55 years of
age), in whom there appeared to be a trend toward benefit.
In the present study, systolic blood pressure declined
with both treatments (no difference between CO and
EVOO); however, both diastolic blood pressure and heart
rate rose slightly during the CO condition compared with
modest declines in the EVOO condition (both P , .05 for
CO vs EVOO). Results from prior investigations have
shown that olive oil consumption decreases blood pressure
and is associated with a reduced risk for developing hyper-
tension.33–36 In a 4-year follow-up of the Prevention with
Mediterranean Diet study, a randomized clinical trial of
the Mediterranean diet in 7447 men and women in Spain,
participants who followed a Mediterranean diet supple-
mented with either EVOO or with nuts experienced signif-
icantly larger reductions in diastolic blood pressure than
subjects who received counseling to follow a low-fat
diet.11,36 The blood pressure-lowering effect of olive oil
may be due to its high oleic acid content.37 Soybean oil,
which, like CO, is low in oleic acid, has not been shown
to affect blood pressure.37 The small reduction in heart
rate with EVOO would also be considered potentially bene-
ficial, because lower heart rate is associated with lower risk
for cardiovascular disease.38 However, the authors are not
aware of any study that has been specifically designed to
investigate the effects of olive oil vs CO on heart rate.
Therefore, this finding is of uncertain clinical relevance
and possible effects of EVOO on heart rate and other hemo-
dynamic variables should be investigated further.
Subjects had excellent compliance with consumption of
the study products and meals, which were provided by the
clinic. The inclusion of the study oils in food products that
individuals would be likely to consume in everyday life (ie,
muffins, dinner rolls, and yogurt) allow generalizability of
these results to a free-living hypercholesterolemic popula-
tion. Although there were a few isolated instances of
changes in body weight, with increases and decreases
observed during both treatment conditions, mean body
weight changed from baseline by #0.6 kg, and there were
no differences in body weight changes between conditions,
suggesting that the meal plan design and monitoring were
generally successful at maintaining stable body weights.
A limitation of this trial was the inclusion of only one
level of intake for each oil. The dose-response profiles withregard to the lipid-altering effects of PUFA and MUFA
have not been fully described. The dose-response to
phytosterol consumption, 1 purported explanation for the
LDL-C–lowering effect of CO, has been investigated.24,39
Another limitation of the trial was the relatively homoge-
neous sample with regard to type of dyslipidemia. Although
all subjects had elevated LDL-C, the mean baseline TG
concentration was in the normal range (,150 mg/dL).
Additional research will be needed to evaluate the effects
of CO vs EVOO in subjects with other dyslipidemias.Conclusion
The results of this study demonstrated that consumption
of CO, as part of a weight-maintenance, low-SFA, and low-
cholesterol diet, by men and women with hypercholester-
olemia, resulted in significantly larger reductions in total-C,
LDL-C, and non–HDL-C compared with EVOO.Acknowledgments
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